X4 Pharmaceuticals, Inc (XFOR) Market Cap & Valuation Ratios
X4 Pharmaceuticals, Inc (XFOR) has a market cap of $321.2M and a price-to-sales ratio of 20.3, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
XFORX4 Pharmaceuticals, IncFollow XFOR — free
—
Price chart with a free account
- Market cap
- 321.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| XFOR | 0.3 | — | 12.8 | — | — | -52% | — | -237% |
| EDIT | 0.4 | — | 4.5 | — | — | +21% | -161% | — |
| FENC | 0.4 | — | 5.3 | — | — | +78% | -2% | -94% |
| RLMD | 0.3 | — | — | — | -13.2% | — | — | -62% |
| CAPR | 0.3 | — | — | — | — | — | — | -88% |
| ENTA | 0.3 | — | 2.3 | — | -10.9% | +0.7% | -90% | -115% |
| KYTX | 0.3 | — | — | — | — | — | — | -110% |
| AVIR | 0.3 | — | 0.3 | — | — | — | — | -91% |
| ZURA | 0.3 | — | — | — | — | — | — | — |
| FULC | 0.3 | — | — | — | — | — | — | -44% |
| ARCT | 0.3 | — | 3.0 | — | — | -76% | -348% | — |
| Median of these 10 | — | 3.0 | — | -12.0% | +11% | -126% | -91% |
; EV/Sales 12.8 vs. 3.0.
Growth vs. price
each dot a company · hover or tap for valuesX4 Pharmaceuticals, Inc — questions
- What is X4 Pharmaceuticals, Inc's market cap?
- $321.2M.
- What is X4 Pharmaceuticals, Inc's price-to-sales ratio?
- 20.3.
Every figure on this page comes from X4 Pharmaceuticals, Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.